8-K: Journey Medical Reports Full-Year 2024 Financial Results and Corporate Highlights

Journey Medical Corporation announces its full-year 2024 financial results, highlighting FDA approval and initial distribution of Emrosi, along with total revenues of $56.1 million.

Summary

• Journey Medical Corporation reported its full-year 2024 financial results on March 26, 2025.
• The company achieved FDA approval for Emrosi in November 2024 and has begun its initial distribution.
• Total revenues for the full year ended December 31, 2024, were $56.1 million.
• This result met all financial guidance for 2024.
• The company's net loss was $(14.7) million, or $(0.72) per share basic and diluted for the full year 2024, compared to the net loss of $(3.9) million or $(0.21) per share basic and diluted for the full year 2023.
• Adjusted EBITDA for the full year 2024 was $0.8 million, or $0.04 per share basic and $0.03 per share diluted, compared to Adjusted EBITDA of $15.6 million, or $0.85 per share basic and $0.75 per share diluted for the full year 2023.
• Cash and cash equivalents totaled $20.3 million as of December 31, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company achieved FDA approval for Emrosi and met its financial guidance, the overall financial performance shows a significant decrease in revenue and a larger net loss compared to the previous year. The management expresses optimism about Emrosi's potential, but the financial results temper the positive outlook.

Positives

• The company received FDA approval for Emrosi ahead of the scheduled PDUFA date.
• Emrosi achieved co-primary and all secondary endpoints in Phase 3 clinical trials with no significant safety issues.
• The company met all financial guidance ranges for 2024.
• The company has begun distribution of Emrosi, and the first prescriptions have been dispensed.
• The company's gross margin percentage slightly improved from period-to-period.

Negatives

• Total revenues decreased by 29% to $56.1 million for 2024, compared to $79.2 million for 2023.
• Product revenue decreased by 8% to $55.1 million for 2024, from $59.7 million for 2023, due to higher rebates and lower unit sales volumes.
• The company's net loss was $(14.7) million for the full year 2024, compared to a net loss of $(3.9) million for the full year 2023.
• Cash and cash equivalents decreased by $7.1 million from the prior-year period, totaling $20.3 million as of December 31, 2024.

Risks

• The company's revenue is dependent mainly upon sales of its dermatology products, and any setback relating to the sale of such products could impair operating results.
• Competition could limit the company's products' commercial opportunity and profitability, including competition from manufacturers of generic versions of its products.
• The company's success depends on the successful commercialization of Emrosi and any future product candidates.
• Clinical drug development is very expensive, time-consuming, and uncertain, and clinical trials may fail to adequately demonstrate the safety and efficacy of current or any future product candidates.
• The company may need to raise additional capital.

Future Outlook

The company expects Emrosi to become the standard of care and transform its business, with full promotion expected in April 2025, and aims to deliver enhanced revenue growth and become sustainably EBITDA positive.

Management Comments

• Claude Maraoui, Journey Medical's Co-Founder, President and Chief Executive Officer, said, 'We delivered a solid performance in 2024, meeting all of our financial guidance ranges and received first cycle FDA approval for Emrosi in November, ahead of the scheduled PDUFA date.'
• Claude Maraoui stated, 'Emrosi's superb Phase 3 clinical results demonstrated its best-in-class profile, and we expect it will become the standard of care and transform our business.'
• Claude Maraoui mentioned, 'Our cash position remains strong ahead of Emrosi's launch and our objective is to deliver enhanced revenue growth and become sustainably EBITDA positive.'
• Claude Maraoui added, 'I am pleased to report that we have begun distribution of Emrosi, that first prescriptions have been dispensed and that we continue to execute ahead of schedule, with full promotion expected in April 2025.'

Industry Context

Journey Medical operates in the dermatology sector, focusing on FDA-approved prescription pharmaceutical products. The approval and launch of Emrosi for rosacea positions the company to compete with existing treatments like Oracea (Doxycycline 40 mg capsules) and potentially capture a significant market share.

Comparison to Industry Standards

• Journey Medical competes with companies like Galderma, the maker of Oracea, in the rosacea treatment market.
• The company's focus on commercializing FDA-approved dermatology products aligns with the strategies of other specialty pharmaceutical companies.
• The decrease in revenue compared to the previous year highlights the challenges in maintaining sales of legacy products in the face of generic competition and changing market dynamics.
• The company's Adjusted EBITDA of $0.8 million for 2024 is significantly lower than the $15.6 million reported for 2023, indicating a need for improved profitability.

Management Changes

Related Party Transactions

• The company had a balance of $528 thousand due to a related party as of December 31, 2024.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the increased net loss.
• Employees may be affected by expense reduction efforts in sales and marketing.
• Customers may benefit from the availability of Emrosi for the treatment of rosacea.
• Suppliers may be impacted by changes in product sales and manufacturing volumes.
• Creditors will monitor the company's financial performance and cash flow.

Next Steps

• Full promotion of Emrosi is expected in April 2025.
• The company will continue to focus on the marketing and sale of its core FDA-approved dermatological products.
• The company will continue to out license its intellectual property and related technologies.

Key Dates

Keywords

Journey Medical, Emrosi, Financial Results, Dermatology, FDA Approval, Revenue, Rosacea, Pharmaceutical